NO315944B1 - CR1 protein for diagnostisk anvendelse in vitro, dets nukleinsyresekvens, rekombinant celle uttrykkende CR1 proteinet og en fremgangsmåte forå rense et CR1 protein - Google Patents

CR1 protein for diagnostisk anvendelse in vitro, dets nukleinsyresekvens, rekombinant celle uttrykkende CR1 proteinet og en fremgangsmåte forå rense et CR1 protein Download PDF

Info

Publication number: NO315944B1
Authority: NO; Norway
Prior art keywords: protein; lhr; fragment; cdna; fragments
Prior art date: 1988-04-01

Application number

NO20000827A

Other languages

English (en)

Norwegian (no)

Other versions

NO20000827D0 (no

NO20000827L (no

Inventor

Douglas T Fearon

Lloyd B Klickstein

Winnie W Wong

Gerald R Carson

Michael F Concino

Stephen H Ip

Savvas C Makrides

Jr Henry C Marsh

Original Assignee

Avant Immunotherapeutics Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1988-04-01

Filing date

2000-02-18

Publication date

2003-11-17

1990-11-09 Publication of NO20000827L publication Critical patent/NO20000827L/no

2000-02-18 Application filed by Avant Immunotherapeutics Inc filed Critical Avant Immunotherapeutics Inc

2000-02-18 Publication of NO20000827D0 publication Critical patent/NO20000827D0/no

2003-11-17 Publication of NO315944B1 publication Critical patent/NO315944B1/no

Links

101000727061 Homo sapiens Complement receptor type 1 Proteins 0.000 title claims abstract description 33
102100030886 Complement receptor type 1 Human genes 0.000 title claims abstract description 25
150000007523 nucleic acids Chemical group 0.000 title claims abstract description 22
238000000034 method Methods 0.000 title claims description 71
108091028043 Nucleic acid sequence Proteins 0.000 title claims description 24
238000000338 in vitro Methods 0.000 title claims description 19
239000012634 fragment Substances 0.000 claims abstract description 227
108090000623 proteins and genes Proteins 0.000 claims abstract description 169
102000004169 proteins and genes Human genes 0.000 claims abstract description 126
239000002773 nucleotide Substances 0.000 claims abstract description 47
125000003729 nucleotide group Chemical group 0.000 claims abstract description 47
125000003275 alpha amino acid group Chemical group 0.000 claims abstract description 29
210000004027 cell Anatomy 0.000 claims description 160
239000013612 plasmid Substances 0.000 claims description 105
230000000295 complement effect Effects 0.000 claims description 56
239000013598 vector Substances 0.000 claims description 54
239000013604 expression vector Substances 0.000 claims description 40
238000004519 manufacturing process Methods 0.000 claims description 35
210000000440 neutrophil Anatomy 0.000 claims description 34
206010018910 Haemolysis Diseases 0.000 claims description 14
230000008588 hemolysis Effects 0.000 claims description 14
238000005277 cation exchange chromatography Methods 0.000 claims description 12
230000001404 mediated effect Effects 0.000 claims description 12
230000001105 regulatory effect Effects 0.000 claims description 10
210000004978 chinese hamster ovary cell Anatomy 0.000 claims description 8
238000010828 elution Methods 0.000 claims description 8
102000039446 nucleic acids Human genes 0.000 claims description 7
108020004707 nucleic acids Proteins 0.000 claims description 7
238000005571 anion exchange chromatography Methods 0.000 claims description 5
230000019254 respiratory burst Effects 0.000 claims description 4
239000012504 chromatography matrix Substances 0.000 claims description 3
239000012930 cell culture fluid Substances 0.000 claims description 2
239000002299 complementary DNA Substances 0.000 abstract description 134
230000014509 gene expression Effects 0.000 abstract description 57
150000001413 amino acids Chemical class 0.000 abstract description 43
108090000765 processed proteins & peptides Proteins 0.000 abstract description 37
102000004196 processed proteins & peptides Human genes 0.000 abstract description 30
238000010367 cloning Methods 0.000 abstract description 25
230000024203 complement activation Effects 0.000 abstract description 16
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 13
206010061218 Inflammation Diseases 0.000 abstract description 7
208000035475 disorder Diseases 0.000 abstract description 7
230000004054 inflammatory process Effects 0.000 abstract description 7
208000010125 myocardial infarction Diseases 0.000 abstract description 7
208000026278 immune system disease Diseases 0.000 abstract description 6
206010063837 Reperfusion injury Diseases 0.000 abstract description 5
208000027866 inflammatory disease Diseases 0.000 abstract description 5
238000002560 therapeutic procedure Methods 0.000 abstract description 5
238000003745 diagnosis Methods 0.000 abstract description 3
230000006378 damage Effects 0.000 abstract description 2
210000000987 immune system Anatomy 0.000 abstract description 2
235000018102 proteins Nutrition 0.000 description 113
108020004414 DNA Proteins 0.000 description 73
102100022133 Complement C3 Human genes 0.000 description 70
101000901154 Homo sapiens Complement C3 Proteins 0.000 description 69
235000001014 amino acid Nutrition 0.000 description 48
229940024606 amino acid Drugs 0.000 description 48
230000027455 binding Effects 0.000 description 48
239000000523 sample Substances 0.000 description 44
210000003743 erythrocyte Anatomy 0.000 description 43
101100006976 Mus musculus C4b gene Proteins 0.000 description 42
101100007625 Homo sapiens CR1 gene Proteins 0.000 description 40
230000000694 effects Effects 0.000 description 40
238000012217 deletion Methods 0.000 description 38
230000037430 deletion Effects 0.000 description 38
102100031506 Complement C5 Human genes 0.000 description 37
BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 32
238000004128 high performance liquid chromatography Methods 0.000 description 32
238000004458 analytical method Methods 0.000 description 30
102000005962 receptors Human genes 0.000 description 28
108020003175 receptors Proteins 0.000 description 28
230000029087 digestion Effects 0.000 description 26
230000006870 function Effects 0.000 description 26
238000000746 purification Methods 0.000 description 26
210000002966 serum Anatomy 0.000 description 25
238000003556 assay Methods 0.000 description 24
238000003776 cleavage reaction Methods 0.000 description 24
230000007017 scission Effects 0.000 description 24
108091026890 Coding region Proteins 0.000 description 23
238000002965 ELISA Methods 0.000 description 23
230000015572 biosynthetic process Effects 0.000 description 23
239000000047 product Substances 0.000 description 22
238000006243 chemical reaction Methods 0.000 description 21
238000010276 construction Methods 0.000 description 21
241000588724 Escherichia coli Species 0.000 description 20
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 20
102100032768 Complement receptor type 2 Human genes 0.000 description 18
101710143772 Complement receptor type 2 Proteins 0.000 description 18
230000005764 inhibitory process Effects 0.000 description 17
239000002609 medium Substances 0.000 description 17
108091008146 restriction endonucleases Proteins 0.000 description 17
238000002835 absorbance Methods 0.000 description 16
230000004913 activation Effects 0.000 description 16
102000014650 luteinizing hormone receptor activity proteins Human genes 0.000 description 16
108020004999 messenger RNA Proteins 0.000 description 16
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 16
102000016550 Complement Factor H Human genes 0.000 description 15
108010053085 Complement Factor H Proteins 0.000 description 15
239000000872 buffer Substances 0.000 description 14
230000001086 cytosolic effect Effects 0.000 description 14
238000009396 hybridization Methods 0.000 description 14
239000000203 mixture Substances 0.000 description 14
229920001184 polypeptide Polymers 0.000 description 14
108010078015 Complement C3b Proteins 0.000 description 13
239000012228 culture supernatant Substances 0.000 description 13
239000000499 gel Substances 0.000 description 13
238000013519 translation Methods 0.000 description 13
108091003079 Bovine Serum Albumin Proteins 0.000 description 12
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 12
241000700159 Rattus Species 0.000 description 12
150000001768 cations Chemical class 0.000 description 12
201000000596 systemic lupus erythematosus Diseases 0.000 description 12
108091032973 (ribonucleotides)n+m Proteins 0.000 description 11
101710159767 C4b-binding protein alpha chain Proteins 0.000 description 11
102100037084 C4b-binding protein alpha chain Human genes 0.000 description 11
108020004511 Recombinant DNA Proteins 0.000 description 11
239000012894 fetal calf serum Substances 0.000 description 11
238000002955 isolation Methods 0.000 description 11
230000037361 pathway Effects 0.000 description 11
241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 10
240000004808 Saccharomyces cerevisiae Species 0.000 description 10
235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 10
210000003719 b-lymphocyte Anatomy 0.000 description 10
238000004113 cell culture Methods 0.000 description 10
210000000170 cell membrane Anatomy 0.000 description 10
239000006166 lysate Substances 0.000 description 10
239000011780 sodium chloride Substances 0.000 description 10
102000014914 Carrier Proteins Human genes 0.000 description 9
238000012300 Sequence Analysis Methods 0.000 description 9
108091008324 binding proteins Proteins 0.000 description 9
239000003599 detergent Substances 0.000 description 9
238000003780 insertion Methods 0.000 description 9
230000037431 insertion Effects 0.000 description 9
239000000463 material Substances 0.000 description 9
230000009467 reduction Effects 0.000 description 9
102000016928 DNA-directed DNA polymerase Human genes 0.000 description 8
108010014303 DNA-directed DNA polymerase Proteins 0.000 description 8
FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 8
241001529936 Murinae Species 0.000 description 8
239000011543 agarose gel Substances 0.000 description 8
229960000723 ampicillin Drugs 0.000 description 8
AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 8
239000000427 antigen Substances 0.000 description 8
108091007433 antigens Proteins 0.000 description 8
102000036639 antigens Human genes 0.000 description 8
238000013459 approach Methods 0.000 description 8
239000013599 cloning vector Substances 0.000 description 8
102000046508 human CR1 Human genes 0.000 description 8
239000003446 ligand Substances 0.000 description 8
229960000485 methotrexate Drugs 0.000 description 8
238000010369 molecular cloning Methods 0.000 description 8
229910052760 oxygen Inorganic materials 0.000 description 8
239000001301 oxygen Substances 0.000 description 8
230000036961 partial effect Effects 0.000 description 8
238000003127 radioimmunoassay Methods 0.000 description 8
230000000638 stimulation Effects 0.000 description 8
238000011144 upstream manufacturing Methods 0.000 description 8
108020004705 Codon Proteins 0.000 description 7
108090000056 Complement factor B Proteins 0.000 description 7
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 7
241000701109 Human adenovirus 2 Species 0.000 description 7
108091034117 Oligonucleotide Proteins 0.000 description 7
108700026244 Open Reading Frames Proteins 0.000 description 7
241001494479 Pecora Species 0.000 description 7
206010057249 Phagocytosis Diseases 0.000 description 7
108091034057 RNA (poly(A)) Proteins 0.000 description 7
241000700605 Viruses Species 0.000 description 7
230000003321 amplification Effects 0.000 description 7
239000008103 glucose Substances 0.000 description 7
238000003199 nucleic acid amplification method Methods 0.000 description 7
239000002245 particle Substances 0.000 description 7
230000008782 phagocytosis Effects 0.000 description 7
238000002360 preparation method Methods 0.000 description 7
239000006228 supernatant Substances 0.000 description 7
238000013518 transcription Methods 0.000 description 7
230000035897 transcription Effects 0.000 description 7
229920000936 Agarose Polymers 0.000 description 6
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
102000003712 Complement factor B Human genes 0.000 description 6
102000004594 DNA Polymerase I Human genes 0.000 description 6
108010017826 DNA Polymerase I Proteins 0.000 description 6
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 6
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 6
ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 6
102000003923 Protein Kinase C Human genes 0.000 description 6
108090000315 Protein Kinase C Proteins 0.000 description 6
108010076504 Protein Sorting Signals Proteins 0.000 description 6
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 6
238000000376 autoradiography Methods 0.000 description 6
230000001580 bacterial effect Effects 0.000 description 6
102000006834 complement receptors Human genes 0.000 description 6
238000010790 dilution Methods 0.000 description 6
239000012895 dilution Substances 0.000 description 6
201000010099 disease Diseases 0.000 description 6
239000001963 growth medium Substances 0.000 description 6
230000002209 hydrophobic effect Effects 0.000 description 6
238000003018 immunoassay Methods 0.000 description 6
238000010166 immunofluorescence Methods 0.000 description 6
230000002779 inactivation Effects 0.000 description 6
239000012528 membrane Substances 0.000 description 6
230000004048 modification Effects 0.000 description 6
238000012986 modification Methods 0.000 description 6
230000008488 polyadenylation Effects 0.000 description 6
230000002797 proteolythic effect Effects 0.000 description 6
239000012679 serum free medium Substances 0.000 description 6
241000701161 unidentified adenovirus Species 0.000 description 6
108700028369 Alleles Proteins 0.000 description 5
108010028778 Complement C4 Proteins 0.000 description 5
108091035707 Consensus sequence Proteins 0.000 description 5
241000701022 Cytomegalovirus Species 0.000 description 5
102000012410 DNA Ligases Human genes 0.000 description 5
108010061982 DNA Ligases Proteins 0.000 description 5
241000620209 Escherichia coli DH5[alpha] Species 0.000 description 5
108091092195 Intron Proteins 0.000 description 5
229930182816 L-glutamine Natural products 0.000 description 5
241000283973 Oryctolagus cuniculus Species 0.000 description 5
102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 5
108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 5
108091081024 Start codon Proteins 0.000 description 5
238000000246 agarose gel electrophoresis Methods 0.000 description 5
150000001450 anions Chemical class 0.000 description 5
230000033228 biological regulation Effects 0.000 description 5
108010052926 complement C3d,g Proteins 0.000 description 5
108010047295 complement receptors Proteins 0.000 description 5
230000001419 dependent effect Effects 0.000 description 5
238000010586 diagram Methods 0.000 description 5
238000001727 in vivo Methods 0.000 description 5
238000011534 incubation Methods 0.000 description 5
230000003993 interaction Effects 0.000 description 5
238000011031 large-scale manufacturing process Methods 0.000 description 5
210000004962 mammalian cell Anatomy 0.000 description 5
239000003550 marker Substances 0.000 description 5
210000001616 monocyte Anatomy 0.000 description 5
210000002741 palatine tonsil Anatomy 0.000 description 5
238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 5
230000003252 repetitive effect Effects 0.000 description 5
238000012163 sequencing technique Methods 0.000 description 5
239000007858 starting material Substances 0.000 description 5
239000000126 substance Substances 0.000 description 5
238000001890 transfection Methods 0.000 description 5
238000011282 treatment Methods 0.000 description 5
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 4
244000144725 Amygdalus communis Species 0.000 description 4
235000011437 Amygdalus communis Nutrition 0.000 description 4
241000282693 Cercopithecidae Species 0.000 description 4
108010067641 Complement C3-C5 Convertases Proteins 0.000 description 4
102000016574 Complement C3-C5 Convertases Human genes 0.000 description 4
102000000989 Complement System Proteins Human genes 0.000 description 4
108010069112 Complement System Proteins Proteins 0.000 description 4
101150074155 DHFR gene Proteins 0.000 description 4
108010052285 Membrane Proteins Proteins 0.000 description 4
BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 4
229920002684 Sepharose Polymers 0.000 description 4
230000005856 abnormality Effects 0.000 description 4
239000002253 acid Substances 0.000 description 4
235000020224 almond Nutrition 0.000 description 4
210000004369 blood Anatomy 0.000 description 4
239000008280 blood Substances 0.000 description 4
230000010261 cell growth Effects 0.000 description 4
239000005546 dideoxynucleotide Substances 0.000 description 4
238000002474 experimental method Methods 0.000 description 4
210000000285 follicular dendritic cell Anatomy 0.000 description 4
230000005714 functional activity Effects 0.000 description 4
230000002068 genetic effect Effects 0.000 description 4
230000013595 glycosylation Effects 0.000 description 4
238000006206 glycosylation reaction Methods 0.000 description 4
230000012010 growth Effects 0.000 description 4
230000002949 hemolytic effect Effects 0.000 description 4
230000001900 immune effect Effects 0.000 description 4
238000001114 immunoprecipitation Methods 0.000 description 4
239000012139 lysis buffer Substances 0.000 description 4
210000002540 macrophage Anatomy 0.000 description 4
238000013507 mapping Methods 0.000 description 4
239000011159 matrix material Substances 0.000 description 4
MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 4
244000005700 microbiome Species 0.000 description 4
125000000896 monocarboxylic acid group Chemical group 0.000 description 4
230000026731 phosphorylation Effects 0.000 description 4
238000006366 phosphorylation reaction Methods 0.000 description 4
230000008569 process Effects 0.000 description 4
238000012545 processing Methods 0.000 description 4
230000006337 proteolytic cleavage Effects 0.000 description 4
230000006798 recombination Effects 0.000 description 4
230000002829 reductive effect Effects 0.000 description 4
241000894007 species Species 0.000 description 4
238000010561 standard procedure Methods 0.000 description 4
230000001225 therapeutic effect Effects 0.000 description 4
230000009466 transformation Effects 0.000 description 4
DIGQNXIGRZPYDK-WKSCXVIASA-N (2R)-6-amino-2-[[2-[[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-[[(2R,3S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2R)-2-[[2-[[2-[[2-[(2-amino-1-hydroxyethylidene)amino]-3-carboxy-1-hydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1,5-dihydroxy-5-iminopentylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]hexanoic acid Chemical compound C[C@@H]([C@@H](C(=N[C@@H](CS)C(=N[C@@H](C)C(=N[C@@H](CO)C(=NCC(=N[C@@H](CCC(=N)O)C(=NC(CS)C(=N[C@H]([C@H](C)O)C(=N[C@H](CS)C(=N[C@H](CO)C(=NCC(=N[C@H](CS)C(=NCC(=N[C@H](CCCCN)C(=O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)N=C([C@H](CS)N=C([C@H](CO)N=C([C@H](CO)N=C([C@H](C)N=C(CN=C([C@H](CO)N=C([C@H](CS)N=C(CN=C(C(CS)N=C(C(CC(=O)O)N=C(CN)O)O)O)O)O)O)O)O)O)O)O)O DIGQNXIGRZPYDK-WKSCXVIASA-N 0.000 description 3
206010001052 Acute respiratory distress syndrome Diseases 0.000 description 3
DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 3
108010028780 Complement C3 Proteins 0.000 description 3
102000016918 Complement C3 Human genes 0.000 description 3
102000001301 EGF receptor Human genes 0.000 description 3
108060006698 EGF receptor Proteins 0.000 description 3
239000004471 Glycine Substances 0.000 description 3
102000014702 Haptoglobin Human genes 0.000 description 3
108050005077 Haptoglobin Proteins 0.000 description 3
108060003951 Immunoglobulin Proteins 0.000 description 3
DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 3
QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 3
208000005777 Lupus Nephritis Diseases 0.000 description 3
108090000157 Metallothionein Proteins 0.000 description 3
102000003792 Metallothionein Human genes 0.000 description 3
101000822667 Mus musculus Something about silencing protein 10 Proteins 0.000 description 3
229910019142 PO4 Inorganic materials 0.000 description 3
208000013616 Respiratory Distress Syndrome Diseases 0.000 description 3
210000001744 T-lymphocyte Anatomy 0.000 description 3
QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 3
YJQCOFNZVFGCAF-UHFFFAOYSA-N Tunicamycin II Natural products O1C(CC(O)C2C(C(O)C(O2)N2C(NC(=O)C=C2)=O)O)C(O)C(O)C(NC(=O)C=CCCCCCCCCC(C)C)C1OC1OC(CO)C(O)C(O)C1NC(C)=O YJQCOFNZVFGCAF-UHFFFAOYSA-N 0.000 description 3
241000700618 Vaccinia virus Species 0.000 description 3
150000007513 acids Chemical class 0.000 description 3
230000009471 action Effects 0.000 description 3
201000000028 adult respiratory distress syndrome Diseases 0.000 description 3
-1 amino acid amino acid Chemical class 0.000 description 3
239000003242 anti bacterial agent Substances 0.000 description 3
229940088710 antibiotic agent Drugs 0.000 description 3
235000009582 asparagine Nutrition 0.000 description 3
229960001230 asparagine Drugs 0.000 description 3
230000000903 blocking effect Effects 0.000 description 3
239000001506 calcium phosphate Substances 0.000 description 3
229910000389 calcium phosphate Inorganic materials 0.000 description 3
230000006037 cell lysis Effects 0.000 description 3
230000001413 cellular effect Effects 0.000 description 3
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
230000004154 complement system Effects 0.000 description 3
235000018417 cysteine Nutrition 0.000 description 3
230000009089 cytolysis Effects 0.000 description 3
238000001514 detection method Methods 0.000 description 3
238000011161 development Methods 0.000 description 3
239000013613 expression plasmid Substances 0.000 description 3
238000012239 gene modification Methods 0.000 description 3
230000005017 genetic modification Effects 0.000 description 3
235000013617 genetically modified food Nutrition 0.000 description 3
210000001282 glomerular podocyte Anatomy 0.000 description 3
101150106093 gpt gene Proteins 0.000 description 3
210000003714 granulocyte Anatomy 0.000 description 3
239000012510 hollow fiber Substances 0.000 description 3
102000018358 immunoglobulin Human genes 0.000 description 3
230000000977 initiatory effect Effects 0.000 description 3
230000002427 irreversible effect Effects 0.000 description 3
210000000265 leukocyte Anatomy 0.000 description 3
230000007193 modulation by symbiont of host erythrocyte aggregation Effects 0.000 description 3
229940092253 ovalbumin Drugs 0.000 description 3
239000012071 phase Substances 0.000 description 3
YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 3
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 3
239000010452 phosphate Substances 0.000 description 3
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
230000010076 replication Effects 0.000 description 3
239000004017 serum-free culture medium Substances 0.000 description 3
230000035939 shock Effects 0.000 description 3
238000003786 synthesis reaction Methods 0.000 description 3
238000012360 testing method Methods 0.000 description 3
ZHSGGJXRNHWHRS-VIDYELAYSA-N tunicamycin Chemical compound O([C@H]1[C@@H]([C@H]([C@@H](O)[C@@H](CC(O)[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C(NC(=O)C=C2)=O)O)O1)O)NC(=O)/C=C/CC(C)C)[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1NC(C)=O ZHSGGJXRNHWHRS-VIDYELAYSA-N 0.000 description 3
MEYZYGMYMLNUHJ-UHFFFAOYSA-N tunicamycin Natural products CC(C)CCCCCCCCCC=CC(=O)NC1C(O)C(O)C(CC(O)C2OC(C(O)C2O)N3C=CC(=O)NC3=O)OC1OC4OC(CO)C(O)C(O)C4NC(=O)C MEYZYGMYMLNUHJ-UHFFFAOYSA-N 0.000 description 3
241000701447 unidentified baculovirus Species 0.000 description 3
230000003612 virological effect Effects 0.000 description 3
238000001262 western blot Methods 0.000 description 3
MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 2
GEYOCULIXLDCMW-UHFFFAOYSA-N 1,2-phenylenediamine Chemical compound NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 description 2
VFNKZQNIXUFLBC-UHFFFAOYSA-N 2',7'-dichlorofluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC(Cl)=C(O)C=C1OC1=C2C=C(Cl)C(O)=C1 VFNKZQNIXUFLBC-UHFFFAOYSA-N 0.000 description 2
FTOAOBMCPZCFFF-UHFFFAOYSA-N 5,5-diethylbarbituric acid Chemical compound CCC1(CC)C(=O)NC(=O)NC1=O FTOAOBMCPZCFFF-UHFFFAOYSA-N 0.000 description 2
239000004475 Arginine Substances 0.000 description 2
208000023275 Autoimmune disease Diseases 0.000 description 2
102000004506 Blood Proteins Human genes 0.000 description 2
101100256223 Caenorhabditis elegans cho-1 gene Proteins 0.000 description 2
241000283707 Capra Species 0.000 description 2
101710091342 Chemotactic peptide Proteins 0.000 description 2
108090000955 Complement C2 Proteins 0.000 description 2
102000053602 DNA Human genes 0.000 description 2
238000007900 DNA-DNA hybridization Methods 0.000 description 2
102000004190 Enzymes Human genes 0.000 description 2
108090000790 Enzymes Proteins 0.000 description 2
108700024394 Exon Proteins 0.000 description 2
206010015866 Extravasation Diseases 0.000 description 2
ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
108010010803 Gelatin Proteins 0.000 description 2
102000003886 Glycoproteins Human genes 0.000 description 2
108090000288 Glycoproteins Proteins 0.000 description 2
108010051696 Growth Hormone Proteins 0.000 description 2
239000012981 Hank's balanced salt solution Substances 0.000 description 2
241000238631 Hexapoda Species 0.000 description 2
108010001336 Horseradish Peroxidase Proteins 0.000 description 2
241000725303 Human immunodeficiency virus Species 0.000 description 2
102000010789 Interleukin-2 Receptors Human genes 0.000 description 2
108010038453 Interleukin-2 Receptors Proteins 0.000 description 2
ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 2
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
102000018697 Membrane Proteins Human genes 0.000 description 2
241001465754 Metazoa Species 0.000 description 2
108020004485 Nonsense Codon Proteins 0.000 description 2
101150064009 PLLP gene Proteins 0.000 description 2
101000777480 Phyllodiscus semoni DELTA-alicitoxin-Pse1b Proteins 0.000 description 2
229920001213 Polysorbate 20 Polymers 0.000 description 2
ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 2
108020005067 RNA Splice Sites Proteins 0.000 description 2
241000219061 Rheum Species 0.000 description 2
PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
102100038803 Somatotropin Human genes 0.000 description 2
238000002105 Southern blotting Methods 0.000 description 2
108020005038 Terminator Codon Proteins 0.000 description 2
239000004098 Tetracycline Substances 0.000 description 2
108091036066 Three prime untranslated region Proteins 0.000 description 2
108010022394 Threonine synthase Proteins 0.000 description 2
239000007983 Tris buffer Substances 0.000 description 2
238000001042 affinity chromatography Methods 0.000 description 2
235000004279 alanine Nutrition 0.000 description 2
125000000539 amino acid group Chemical group 0.000 description 2
230000003357 anti-levan Effects 0.000 description 2
239000008346 aqueous phase Substances 0.000 description 2
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
238000000211 autoradiogram Methods 0.000 description 2
239000011324 bead Substances 0.000 description 2
230000008901 benefit Effects 0.000 description 2
238000001574 biopsy Methods 0.000 description 2
210000004899 c-terminal region Anatomy 0.000 description 2
229910052793 cadmium Inorganic materials 0.000 description 2
BDOSMKKIYDKNTQ-UHFFFAOYSA-N cadmium atom Chemical compound [Cd] BDOSMKKIYDKNTQ-UHFFFAOYSA-N 0.000 description 2
YKYOUMDCQGMQQO-UHFFFAOYSA-L cadmium dichloride Chemical compound Cl[Cd]Cl YKYOUMDCQGMQQO-UHFFFAOYSA-L 0.000 description 2
235000011010 calcium phosphates Nutrition 0.000 description 2
101150055766 cat gene Proteins 0.000 description 2
230000015556 catabolic process Effects 0.000 description 2
239000006143 cell culture medium Substances 0.000 description 2
210000002421 cell wall Anatomy 0.000 description 2
230000008859 change Effects 0.000 description 2
238000004587 chromatography analysis Methods 0.000 description 2
238000004440 column chromatography Methods 0.000 description 2
238000012258 culturing Methods 0.000 description 2
238000005520 cutting process Methods 0.000 description 2
125000000151 cysteine group Chemical class N[C@@H](CS)C(=O)* 0.000 description 2
238000006731 degradation reaction Methods 0.000 description 2
102000004419 dihydrofolate reductase Human genes 0.000 description 2
238000010494 dissociation reaction Methods 0.000 description 2
230000005593 dissociations Effects 0.000 description 2
229940088598 enzyme Drugs 0.000 description 2
238000009585 enzyme analysis Methods 0.000 description 2
210000003617 erythrocyte membrane Anatomy 0.000 description 2
230000036251 extravasation Effects 0.000 description 2
238000000684 flow cytometry Methods 0.000 description 2
238000005194 fractionation Methods 0.000 description 2
239000007789 gas Substances 0.000 description 2
239000008273 gelatin Substances 0.000 description 2
229920000159 gelatin Polymers 0.000 description 2
235000019322 gelatine Nutrition 0.000 description 2
235000011852 gelatine desserts Nutrition 0.000 description 2
239000000122 growth hormone Substances 0.000 description 2
210000005260 human cell Anatomy 0.000 description 2
239000000411 inducer Substances 0.000 description 2
208000015181 infectious disease Diseases 0.000 description 2
230000008595 infiltration Effects 0.000 description 2
238000001764 infiltration Methods 0.000 description 2
238000002347 injection Methods 0.000 description 2
239000007924 injection Substances 0.000 description 2
230000007246 mechanism Effects 0.000 description 2
230000000813 microbial effect Effects 0.000 description 2
238000000386 microscopy Methods 0.000 description 2
230000005012 migration Effects 0.000 description 2
238000013508 migration Methods 0.000 description 2
230000037230 mobility Effects 0.000 description 2
201000008383 nephritis Diseases 0.000 description 2
108091027963 non-coding RNA Proteins 0.000 description 2
102000042567 non-coding RNA Human genes 0.000 description 2
238000007899 nucleic acid hybridization Methods 0.000 description 2
229920001542 oligosaccharide Polymers 0.000 description 2
150000002482 oligosaccharides Chemical class 0.000 description 2
230000003647 oxidation Effects 0.000 description 2
238000007254 oxidation reaction Methods 0.000 description 2
239000008188 pellet Substances 0.000 description 2
150000004633 phorbol derivatives Chemical class 0.000 description 2
239000002644 phorbol ester Substances 0.000 description 2
210000000557 podocyte Anatomy 0.000 description 2
229920002401 polyacrylamide Polymers 0.000 description 2
239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
210000002729 polyribosome Anatomy 0.000 description 2
239000002243 precursor Substances 0.000 description 2
238000003259 recombinant expression Methods 0.000 description 2
238000005215 recombination Methods 0.000 description 2
230000009711 regulatory function Effects 0.000 description 2
238000011160 research Methods 0.000 description 2
238000010839 reverse transcription Methods 0.000 description 2
238000007390 skin biopsy Methods 0.000 description 2
239000001488 sodium phosphate Substances 0.000 description 2
229910000162 sodium phosphate Inorganic materials 0.000 description 2
239000011537 solubilization buffer Substances 0.000 description 2
230000003393 splenic effect Effects 0.000 description 2
238000012916 structural analysis Methods 0.000 description 2
238000006467 substitution reaction Methods 0.000 description 2
239000000758 substrate Substances 0.000 description 2
230000008685 targeting Effects 0.000 description 2
229960002180 tetracycline Drugs 0.000 description 2
229930101283 tetracycline Natural products 0.000 description 2
235000019364 tetracycline Nutrition 0.000 description 2
150000003522 tetracyclines Chemical class 0.000 description 2
210000001519 tissue Anatomy 0.000 description 2
230000000451 tissue damage Effects 0.000 description 2
231100000827 tissue damage Toxicity 0.000 description 2
230000010474 transient expression Effects 0.000 description 2
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 2
238000000108 ultra-filtration Methods 0.000 description 2
241001515965 unidentified phage Species 0.000 description 2
JWDFQMWEFLOOED-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-(pyridin-2-yldisulfanyl)propanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCSSC1=CC=CC=N1 JWDFQMWEFLOOED-UHFFFAOYSA-N 0.000 description 1
JLAKDWUZBRFSTL-UHFFFAOYSA-N 1-[2-(4-azidophenyl)propan-2-ylamino]-3-(9h-carbazol-4-yloxy)propan-2-ol Chemical compound C=1C=CC=2NC3=CC=CC=C3C=2C=1OCC(O)CNC(C)(C)C1=CC=C(N=[N+]=[N-])C=C1 JLAKDWUZBRFSTL-UHFFFAOYSA-N 0.000 description 1
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
MKFZBANYYHZIGG-UHFFFAOYSA-N 3,5-dichloro-1,7-diphenylheptan-4-one Chemical compound C=1C=CC=CC=1CCC(Cl)C(=O)C(Cl)CCC1=CC=CC=C1 MKFZBANYYHZIGG-UHFFFAOYSA-N 0.000 description 1
NEEVCWPRIZJJRJ-UHFFFAOYSA-N 5,6-bis(benzylideneamino)-2-sulfanylidene-1H-pyrimidin-4-one Chemical compound C=1C=CC=CC=1C=NC=1C(O)=NC(S)=NC=1N=CC1=CC=CC=C1 NEEVCWPRIZJJRJ-UHFFFAOYSA-N 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
102000002260 Alkaline Phosphatase Human genes 0.000 description 1
108020004774 Alkaline Phosphatase Proteins 0.000 description 1
108010089414 Anaphylatoxins Proteins 0.000 description 1
229930091051 Arenine Natural products 0.000 description 1
241000894006 Bacteria Species 0.000 description 1
108010017384 Blood Proteins Proteins 0.000 description 1
101100243951 Caenorhabditis elegans pie-1 gene Proteins 0.000 description 1
241000700198 Cavia Species 0.000 description 1
241000700199 Cavia porcellus Species 0.000 description 1
108090000317 Chymotrypsin Proteins 0.000 description 1
108010034358 Classical Pathway Complement C3 Convertase Proteins 0.000 description 1
102100031609 Complement C2 Human genes 0.000 description 1
102000004381 Complement C2 Human genes 0.000 description 1
108010078075 Complement C2b Proteins 0.000 description 1
108010077762 Complement C4b Proteins 0.000 description 1
108010078546 Complement C5a Proteins 0.000 description 1
108020004635 Complementary DNA Proteins 0.000 description 1
238000001712 DNA sequencing Methods 0.000 description 1
229920002307 Dextran Polymers 0.000 description 1
229920002491 Diethylaminoethyl-dextran Polymers 0.000 description 1
102100024746 Dihydrofolate reductase Human genes 0.000 description 1
239000006144 Dulbecco’s modiﬁed Eagle's medium Substances 0.000 description 1
241001452028 Escherichia coli DH1 Species 0.000 description 1
108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
108010071289 Factor XIII Proteins 0.000 description 1
102000008857 Ferritin Human genes 0.000 description 1
108050000784 Ferritin Proteins 0.000 description 1
238000008416 Ferritin Methods 0.000 description 1
102000016359 Fibronectins Human genes 0.000 description 1
108010067306 Fibronectins Proteins 0.000 description 1
102000006395 Globulins Human genes 0.000 description 1
108010044091 Globulins Proteins 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
108010051815 Glutamyl endopeptidase Proteins 0.000 description 1
101000740685 Homo sapiens C4b-binding protein alpha chain Proteins 0.000 description 1
101000587539 Homo sapiens Metallothionein-1A Proteins 0.000 description 1
206010020751 Hypersensitivity Diseases 0.000 description 1
108020005350 Initiator Codon Proteins 0.000 description 1
XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
108091026898 Leader sequence (mRNA) Proteins 0.000 description 1
206010024229 Leprosy Diseases 0.000 description 1
ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
239000000232 Lipid Bilayer Substances 0.000 description 1
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
239000004472 Lysine Substances 0.000 description 1
PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 1
108010090665 Mannosyl-Glycoprotein Endo-beta-N-Acetylglucosaminidase Proteins 0.000 description 1
101000969137 Mus musculus Metallothionein-1 Proteins 0.000 description 1
230000004988 N-glycosylation Effects 0.000 description 1
241001045988 Neogene Species 0.000 description 1
229930193140 Neomycin Natural products 0.000 description 1
239000000020 Nitrocellulose Substances 0.000 description 1
238000000636 Northern blotting Methods 0.000 description 1
108091005461 Nucleic proteins Proteins 0.000 description 1
241000784303 Ochrosia compta Species 0.000 description 1
108700020796 Oncogene Proteins 0.000 description 1
102000043276 Oncogene Human genes 0.000 description 1
108010058846 Ovalbumin Proteins 0.000 description 1
108090000526 Papain Proteins 0.000 description 1
241001073889 Peach mosaic virus Species 0.000 description 1
241000364057 Peoria Species 0.000 description 1
108010033276 Peptide Fragments Proteins 0.000 description 1
102000007079 Peptide Fragments Human genes 0.000 description 1
108010033737 Pokeweed Mitogens Proteins 0.000 description 1
241000276498 Pollachius virens Species 0.000 description 1
239000004365 Protease Substances 0.000 description 1
238000002123 RNA extraction Methods 0.000 description 1
230000006819 RNA synthesis Effects 0.000 description 1
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
XYVMBSCIEDOIJQ-UHFFFAOYSA-N Squamolone Chemical compound NC(=O)N1CCCC1=O XYVMBSCIEDOIJQ-UHFFFAOYSA-N 0.000 description 1
AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
239000004473 Threonine Substances 0.000 description 1
102000006601 Thymidine Kinase Human genes 0.000 description 1
108020004440 Thymidine kinase Proteins 0.000 description 1
108090000631 Trypsin Proteins 0.000 description 1
102000004142 Trypsin Human genes 0.000 description 1
KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
108010027570 Xanthine phosphoribosyltransferase Proteins 0.000 description 1
229920000392 Zymosan Polymers 0.000 description 1
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
MZVQCMJNVPIDEA-UHFFFAOYSA-N [CH2]CN(CC)CC Chemical compound [CH2]CN(CC)CC MZVQCMJNVPIDEA-UHFFFAOYSA-N 0.000 description 1
238000009825 accumulation Methods 0.000 description 1
239000000061 acid fraction Substances 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
230000003213 activating effect Effects 0.000 description 1
239000012190 activator Substances 0.000 description 1
230000010933 acylation Effects 0.000 description 1
238000005917 acylation reaction Methods 0.000 description 1
239000000654 additive Substances 0.000 description 1
230000000996 additive effect Effects 0.000 description 1
230000001464 adherent effect Effects 0.000 description 1
230000000274 adsorptive effect Effects 0.000 description 1
208000011341 adult acute respiratory distress syndrome Diseases 0.000 description 1
238000001261 affinity purification Methods 0.000 description 1
238000007818 agglutination assay Methods 0.000 description 1
125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 1
BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
229910052921 ammonium sulfate Inorganic materials 0.000 description 1
238000012870 ammonium sulfate precipitation Methods 0.000 description 1
235000011130 ammonium sulphate Nutrition 0.000 description 1
239000012491 analyte Substances 0.000 description 1
125000000129 anionic group Chemical group 0.000 description 1
238000000137 annealing Methods 0.000 description 1
230000002391 anti-complement effect Effects 0.000 description 1
230000000692 anti-sense effect Effects 0.000 description 1
238000011091 antibody purification Methods 0.000 description 1
108010008730 anticomplement Proteins 0.000 description 1
230000030741 antigen processing and presentation Effects 0.000 description 1
230000000890 antigenic effect Effects 0.000 description 1
206010003246 arthritis Diseases 0.000 description 1
150000001508 asparagines Chemical class 0.000 description 1
235000003704 aspartic acid Nutrition 0.000 description 1
239000013602 bacteriophage vector Substances 0.000 description 1
229960002319 barbital Drugs 0.000 description 1
OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
238000004166 bioassay Methods 0.000 description 1
229960000074 biopharmaceutical Drugs 0.000 description 1
210000004204 blood vessel Anatomy 0.000 description 1
210000001124 body fluid Anatomy 0.000 description 1
239000010839 body fluid Substances 0.000 description 1
238000009835 boiling Methods 0.000 description 1
238000006664 bond formation reaction Methods 0.000 description 1
239000007975 buffered saline Substances 0.000 description 1
238000010804 cDNA synthesis Methods 0.000 description 1
238000004422 calculation algorithm Methods 0.000 description 1
238000004364 calculation method Methods 0.000 description 1
244000309466 calf Species 0.000 description 1
238000005341 cation exchange Methods 0.000 description 1
230000003915 cell function Effects 0.000 description 1
239000013592 cell lysate Substances 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
238000012512 characterization method Methods 0.000 description 1
238000007385 chemical modification Methods 0.000 description 1
239000007795 chemical reaction product Substances 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
230000035605 chemotaxis Effects 0.000 description 1
238000011210 chromatographic step Methods 0.000 description 1
210000000349 chromosome Anatomy 0.000 description 1
229960002376 chymotrypsin Drugs 0.000 description 1
238000000975 co-precipitation Methods 0.000 description 1
230000015271 coagulation Effects 0.000 description 1
238000005345 coagulation Methods 0.000 description 1
210000001072 colon Anatomy 0.000 description 1
238000004891 communication Methods 0.000 description 1
238000012875 competitive assay Methods 0.000 description 1
230000002860 competitive effect Effects 0.000 description 1
238000002967 competitive immunoassay Methods 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
238000005094 computer simulation Methods 0.000 description 1
238000012790 confirmation Methods 0.000 description 1
239000013058 crude material Substances 0.000 description 1
ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 1
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
210000000805 cytoplasm Anatomy 0.000 description 1
RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
230000007812 deficiency Effects 0.000 description 1
230000002939 deleterious effect Effects 0.000 description 1
210000004443 dendritic cell Anatomy 0.000 description 1
230000008021 deposition Effects 0.000 description 1
238000009792 diffusion process Methods 0.000 description 1
108020001096 dihydrofolate reductase Proteins 0.000 description 1
230000009266 disease activity Effects 0.000 description 1
229910000397 disodium phosphate Inorganic materials 0.000 description 1
238000009826 distribution Methods 0.000 description 1
231100000673 dose–response relationship Toxicity 0.000 description 1
230000002500 effect on skin Effects 0.000 description 1
238000001493 electron microscopy Methods 0.000 description 1
238000001962 electrophoresis Methods 0.000 description 1
238000004520 electroporation Methods 0.000 description 1
238000005538 encapsulation Methods 0.000 description 1
230000012202 endocytosis Effects 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
230000002255 enzymatic effect Effects 0.000 description 1
230000009144 enzymatic modification Effects 0.000 description 1
238000001976 enzyme digestion Methods 0.000 description 1
210000003979 eosinophil Anatomy 0.000 description 1
210000004920 epithelial cell of skin Anatomy 0.000 description 1
230000001747 exhibiting effect Effects 0.000 description 1
108010052305 exodeoxyribonuclease III Proteins 0.000 description 1
210000002744 extracellular matrix Anatomy 0.000 description 1
229940012444 factor xiii Drugs 0.000 description 1
239000012091 fetal bovine serum Substances 0.000 description 1
210000002950 fibroblast Anatomy 0.000 description 1
238000011049 filling Methods 0.000 description 1
GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
230000022244 formylation Effects 0.000 description 1
238000006170 formylation reaction Methods 0.000 description 1
238000002825 functional assay Methods 0.000 description 1
230000004927 fusion Effects 0.000 description 1
238000001502 gel electrophoresis Methods 0.000 description 1
238000001415 gene therapy Methods 0.000 description 1
238000012252 genetic analysis Methods 0.000 description 1
239000011521 glass Substances 0.000 description 1
235000013922 glutamic acid Nutrition 0.000 description 1
239000004220 glutamic acid Substances 0.000 description 1
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
235000004554 glutamine Nutrition 0.000 description 1
150000004676 glycans Chemical class 0.000 description 1
150000002337 glycosamines Chemical class 0.000 description 1
229910001385 heavy metal Inorganic materials 0.000 description 1
210000003958 hematopoietic stem cell Anatomy 0.000 description 1
208000007475 hemolytic anemia Diseases 0.000 description 1
210000003630 histaminocyte Anatomy 0.000 description 1
HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
229920001519 homopolymer Polymers 0.000 description 1
210000004754 hybrid cell Anatomy 0.000 description 1
238000002169 hydrotherapy Methods 0.000 description 1
230000014726 immortalization of host cell Effects 0.000 description 1
230000008105 immune reaction Effects 0.000 description 1
230000028993 immune response Effects 0.000 description 1
230000036039 immunity Effects 0.000 description 1
230000003053 immunization Effects 0.000 description 1
238000002649 immunization Methods 0.000 description 1
238000000760 immunoelectrophoresis Methods 0.000 description 1
230000005847 immunogenicity Effects 0.000 description 1
230000016784 immunoglobulin production Effects 0.000 description 1
239000012133 immunoprecipitate Substances 0.000 description 1
230000006872 improvement Effects 0.000 description 1
238000007901 in situ hybridization Methods 0.000 description 1
230000006698 induction Effects 0.000 description 1
230000004968 inflammatory condition Effects 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
208000014674 injury Diseases 0.000 description 1
238000011081 inoculation Methods 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
238000010253 intravenous injection Methods 0.000 description 1
230000026045 iodination Effects 0.000 description 1
238000006192 iodination reaction Methods 0.000 description 1
PGLTVOMIXTUURA-UHFFFAOYSA-N iodoacetamide Chemical compound NC(=O)CI PGLTVOMIXTUURA-UHFFFAOYSA-N 0.000 description 1
238000005342 ion exchange Methods 0.000 description 1
230000000302 ischemic effect Effects 0.000 description 1
238000001155 isoelectric focusing Methods 0.000 description 1
AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
229960000310 isoleucine Drugs 0.000 description 1
210000003734 kidney Anatomy 0.000 description 1
230000003902 lesion Effects 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
239000002502 liposome Substances 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
206010025135 lupus erythematosus Diseases 0.000 description 1
229910052748 manganese Inorganic materials 0.000 description 1
239000011572 manganese Substances 0.000 description 1
238000005259 measurement Methods 0.000 description 1
230000002503 metabolic effect Effects 0.000 description 1
229930182817 methionine Natural products 0.000 description 1
238000000302 molecular modelling Methods 0.000 description 1
210000005087 mononuclear cell Anatomy 0.000 description 1
238000002703 mutagenesis Methods 0.000 description 1
231100000350 mutagenesis Toxicity 0.000 description 1
101150091879 neo gene Proteins 0.000 description 1
229960004927 neomycin Drugs 0.000 description 1
SLCVBVWXLSEKPL-UHFFFAOYSA-N neopentyl glycol Chemical compound OCC(C)(C)CO SLCVBVWXLSEKPL-UHFFFAOYSA-N 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
229920001220 nitrocellulos Polymers 0.000 description 1
230000036963 noncompetitive effect Effects 0.000 description 1
239000002777 nucleoside Substances 0.000 description 1
125000003835 nucleoside group Chemical group 0.000 description 1
230000014207 opsonization Effects 0.000 description 1
238000005457 optimization Methods 0.000 description 1
230000008520 organization Effects 0.000 description 1
229940055729 papain Drugs 0.000 description 1
235000019834 papain Nutrition 0.000 description 1
239000011236 particulate material Substances 0.000 description 1
238000010647 peptide synthesis reaction Methods 0.000 description 1
230000035699 permeability Effects 0.000 description 1
210000001539 phagocyte Anatomy 0.000 description 1
230000002399 phagocytotic effect Effects 0.000 description 1
238000002135 phase contrast microscopy Methods 0.000 description 1
COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
238000007747 plating Methods 0.000 description 1
102000054765 polymorphisms of proteins Human genes 0.000 description 1
229920001282 polysaccharide Polymers 0.000 description 1
239000005017 polysaccharide Substances 0.000 description 1
239000011148 porous material Substances 0.000 description 1
230000001323 posttranslational effect Effects 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
230000002265 prevention Effects 0.000 description 1
230000002062 proliferating effect Effects 0.000 description 1
230000035755 proliferation Effects 0.000 description 1
201000008171 proliferative glomerulonephritis Diseases 0.000 description 1
230000000644 propagated effect Effects 0.000 description 1
238000002731 protein assay Methods 0.000 description 1
238000000159 protein binding assay Methods 0.000 description 1
230000009145 protein modification Effects 0.000 description 1
239000013014 purified material Substances 0.000 description 1
230000035484 reaction time Effects 0.000 description 1
238000006722 reduction reaction Methods 0.000 description 1
230000003362 replicative effect Effects 0.000 description 1
230000004044 response Effects 0.000 description 1
238000004007 reversed phase HPLC Methods 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
238000013341 scale-up Methods 0.000 description 1
238000012216 screening Methods 0.000 description 1
238000010187 selection method Methods 0.000 description 1
238000011451 sequencing strategy Methods 0.000 description 1
238000013207 serial dilution Methods 0.000 description 1
235000004400 serine Nutrition 0.000 description 1
238000002741 site-directed mutagenesis Methods 0.000 description 1
210000000329 smooth muscle myocyte Anatomy 0.000 description 1
239000001509 sodium citrate Substances 0.000 description 1
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
238000005063 solubilization Methods 0.000 description 1
230000007928 solubilization Effects 0.000 description 1
239000000243 solution Substances 0.000 description 1
239000002904 solvent Substances 0.000 description 1
238000000527 sonication Methods 0.000 description 1
238000001179 sorption measurement Methods 0.000 description 1
238000010186 staining Methods 0.000 description 1
229960005322 streptomycin Drugs 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
150000003462 sulfoxides Chemical class 0.000 description 1
239000013589 supplement Substances 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
230000002194 synthesizing effect Effects 0.000 description 1
238000010189 synthetic method Methods 0.000 description 1
RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
229940033663 thimerosal Drugs 0.000 description 1
125000003396 thiol group Chemical group [H]S* 0.000 description 1
235000008521 threonine Nutrition 0.000 description 1
208000037816 tissue injury Diseases 0.000 description 1
LMYRWZFENFIFIT-UHFFFAOYSA-N toluene-4-sulfonamide Chemical compound CC1=CC=C(S(N)(=O)=O)C=C1 LMYRWZFENFIFIT-UHFFFAOYSA-N 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
239000003053 toxin Substances 0.000 description 1
231100000765 toxin Toxicity 0.000 description 1
108700012359 toxins Proteins 0.000 description 1
230000002103 transcriptional effect Effects 0.000 description 1
238000012546 transfer Methods 0.000 description 1
230000001131 transforming effect Effects 0.000 description 1
230000032258 transport Effects 0.000 description 1
230000008733 trauma Effects 0.000 description 1
239000012588 trypsin Substances 0.000 description 1
229960001322 trypsin Drugs 0.000 description 1
108010087967 type I signal peptidase Proteins 0.000 description 1
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
235000002374 tyrosine Nutrition 0.000 description 1
125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
239000004474 valine Substances 0.000 description 1
230000002792 vascular Effects 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
238000002424 x-ray crystallography Methods 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
- C07K14/3153—Streptokinase
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Public Health (AREA)
Immunology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Animal Behavior & Ethology (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Gastroenterology & Hepatology (AREA)
Oncology (AREA)
Toxicology (AREA)
Hematology (AREA)
Diabetes (AREA)
Transplantation (AREA)
Vascular Medicine (AREA)
Cell Biology (AREA)
Communicable Diseases (AREA)
Zoology (AREA)
Urology & Nephrology (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Peptides Or Proteins (AREA)
Joining Of Building Structures In Genera (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)

NO20000827A 1988-04-01 2000-02-18 CR1 protein for diagnostisk anvendelse in vitro, dets nukleinsyresekvens, rekombinant celle uttrykkende CR1 proteinet og en fremgangsmåte forå rense et CR1 protein NO315944B1 (no)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US17653288A	1988-04-01	1988-04-01
PCT/US1989/001358 WO1989009220A1 (en)	1988-04-01	1989-03-31	THE HUMAN C3b/C4b RECEPTOR (CR1)
US41274589A	1989-09-26	1989-09-26

Publications (3)

Publication Number	Publication Date
NO20000827L NO20000827L (no)	1990-11-09
NO20000827D0 NO20000827D0 (no)	2000-02-18
NO315944B1 true NO315944B1 (no)	2003-11-17

Family

ID=26872337

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20000827A NO315944B1 (no)	1988-04-01	2000-02-18	CR1 protein for diagnostisk anvendelse in vitro, dets nukleinsyresekvens, rekombinant celle uttrykkende CR1 proteinet og en fremgangsmåte forå rense et CR1 protein

Country Status (14)

Country	Link
EP (1)	EP0411031B1 (de)
JP (1)	JP3484189B2 (de)
CN (2)	CN1092712C (de)
AT (1)	ATE240973T1 (de)
CA (2)	CA1340866C (de)
DE (1)	DE68929466T2 (de)
DK (1)	DK175699B1 (de)
ES (1)	ES2014593A6 (de)
FI (2)	FI106316B (de)
IL (1)	IL89790A (de)
NO (1)	NO315944B1 (de)
SG (1)	SG52789A1 (de)
WO (1)	WO1989009220A1 (de)
ZA (2)	ZA892397B (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5426029A (en) *	1986-03-31	1995-06-20	T Cell Diagnostics, Inc.	Therapeutic and diagnostic methods using leukocyte surface antigens
US5256642A (en) *	1988-04-01	1993-10-26	The Johns Hopkins University	Compositions of soluble complement receptor 1 (CR1) and a thrombolytic agent, and the methods of use thereof
US6482404B1 (en)	1989-10-12	2002-11-19	David James White	Transplantation of tissue comprising a DNA sequence encoding a homologous complement restriction factor
ES2060561T3 (es)	1989-10-12	1996-08-01	Imutran Ltd	Material biologico modificado.
US6552170B1 (en)	1990-04-06	2003-04-22	Amgen Inc.	PEGylation reagents and compounds formed therewith
US6458360B1 (en) *	1990-04-25	2002-10-01	The Johns Hopkins University	Soluble complement regulatory molecules
JP4236698B2 (ja) *	1990-11-26	2009-03-11	ジェネティックスインスティチュート，リミテッドライアビリティカンパニー	宿主細胞でのｐａｃｅの発現およびその使用法
CA2097825A1 (en) *	1990-12-06	1992-06-07	Henry C. Marsh, Jr.	Synergistic compositions of soluble complement receptors and compounds that inhibit complement and/or suppress immune activity
EP1413587A2 (de) *	1991-05-03	2004-04-28	Washington University	Modifizierter Regulator des Komplementsystems
DE69328098T2 (de) *	1992-06-24	2000-08-24	Adprotech Plc	Lösliche derivate des complement type-rezeptors (cr1)
US5456909A (en) *	1992-08-07	1995-10-10	T Cell Sciences, Inc.	Glycoform fractions of recombinant soluble complement receptor 1 (sCR1) having extended half-lives in vivo
ATE223230T1 (de) *	1993-02-12	2002-09-15	Avant Immunotherapeutics Inc	Pulmonäre verabreichung des löslichen komplement- receptors typ 1 scr1
BR9708387A (pt)	1996-03-28	2000-01-04	Genitrix Llc	Processo para vacinação de um mamìfero a um antìgeno selecionado, células patogênica e hospedeira, composição de vacina, ácido nucleico, e, opsonina engenheirada.
TW555765B (en)	1996-07-09	2003-10-01	Amgen Inc	Low molecular weight soluble tumor necrosis factor type-I and type-II proteins
GB9706950D0 (en) *	1997-04-05	1997-05-21	Chernajovsky Yuti	Immune modulation by polypeptides related to CR1
AU5317499A (en) *	1998-07-24	2000-02-14	Uab Research Foundation	Genetic polymorphism in a complement receptor
US6664052B1 (en)	1998-07-24	2003-12-16	The Uab Research Foundation	Genetic polymorphism in a complement receptor
GB9905503D0 (en)	1999-03-10	1999-05-05	Adprotech Plc	Novel compound formulations and methods of delivery
EP1738763A1 (de)	2005-06-30	2007-01-03	AVANT Immunotherapeutics, Inc.	Verwendung eines Komplement-inhibierenden Proteins zur Behandlung von Rückenmarksverletzungen
US8703136B2 (en)	2006-10-10	2014-04-22	Regenesance B.V.	Complement inhibition for improved nerve regeneration
WO2010047793A2 (en)	2008-10-21	2010-04-29	The General Hospital Corporation	Cell transplantation
US10184110B2 (en)	2010-08-06	2019-01-22	The General Hospital Corporation	System and apparatus for cell treatment
CN103237557A (zh)	2010-09-15	2013-08-07	赛尔戴克斯治疗公司	用可溶性I型补体受体(sCR1)治疗慢性肾病
BR112013010098A2 (pt)	2010-10-27	2017-06-13	Celldex Therapeutics Inc	método para melhorar a função de transplante usando um receptor do complemento solúvel tipo i (scr1)
EP3095876A1 (de)	2010-11-02	2016-11-23	Kypha, Inc.	Querfluss-immuntest für komplement-aktivierung und verfahren zur verwendung zur prüfung auf komplement-assoziierte erkrankungen am versorgungsort
CN102702339B (zh) *	2011-05-24	2013-10-30	华南师范大学	斜带石斑鱼补体c3基因、载体、重组菌株和蛋白及其应用
BR112014013205A2 (pt) *	2011-12-01	2020-10-27	Protevobio, Inc.	proteína de fusão, seu uso e seu método de produção, composição farmacêutica, ácido nucleico, e kit
WO2013082458A1 (en)	2011-12-02	2013-06-06	The Regents Of The University Of California	Reperfusion protection solution and uses thereof
CN104293836A (zh) *	2014-06-24	2015-01-21	长沙赢润生物技术有限公司	一种免疫复合物吸附细胞的制作方法
GB201800620D0 (en)	2018-01-15	2018-02-28	Univ Manchester	C3b Binding Polypeptide
EP3760645A1 (de) *	2019-07-02	2021-01-06	imusyn GmbH & Co. KG	Analyse für das blutgruppenantigen dacy

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS60192948A (ja) *	1984-03-14	1985-10-01	Fuji Photo Film Co Ltd	湿し水不要ネガ型感光性平版印刷版および製版方法
US4672044A (en) *	1984-08-24	1987-06-09	Scripps Clinic & Research Foundation	Murine monoclonal antibody combining site to human C3b receptor (CR1)

1989
- 1989-03-29 IL IL8979089A patent/IL89790A/en active IP Right Grant
- 1989-03-31 DE DE68929466T patent/DE68929466T2/de not_active Expired - Fee Related
- 1989-03-31 JP JP50500089A patent/JP3484189B2/ja not_active Expired - Fee Related
- 1989-03-31 ES ES8901125A patent/ES2014593A6/es not_active Expired - Lifetime
- 1989-03-31 EP EP89905249A patent/EP0411031B1/de not_active Expired - Lifetime
- 1989-03-31 WO PCT/US1989/001358 patent/WO1989009220A1/en active IP Right Grant
- 1989-03-31 SG SG1996009545A patent/SG52789A1/en unknown
- 1989-03-31 AT AT89905249T patent/ATE240973T1/de not_active IP Right Cessation
- 1989-03-31 CA CA000595389A patent/CA1340866C/en not_active Expired - Fee Related
- 1989-03-31 ZA ZA892397A patent/ZA892397B/xx unknown
- 1989-03-31 CA CA000617127A patent/CA1341443C/en not_active Expired - Fee Related
- 1989-04-01 CN CN89101990A patent/CN1092712C/zh not_active Expired - Fee Related
1990
- 1990-09-26 ZA ZA907693A patent/ZA907693B/xx unknown
- 1990-09-26 CN CN90108145A patent/CN1053924C/zh not_active Expired - Fee Related
- 1990-09-28 DK DK199002348A patent/DK175699B1/da not_active IP Right Cessation
- 1990-10-01 FI FI904842A patent/FI106316B/fi active IP Right Grant
2000
- 2000-02-18 NO NO20000827A patent/NO315944B1/no not_active IP Right Cessation
- 2000-11-16 FI FI20002515A patent/FI115528B/fi active IP Right Grant

Also Published As

Publication number	Publication date
JP3484189B2 (ja)	2004-01-06
IL89790A (en)	2002-05-23
SG52789A1 (en)	1998-09-28
WO1989009220A1 (en)	1989-10-05
CN1036987A (zh)	1989-11-08
NO20000827D0 (no)	2000-02-18
NO20000827L (no)	1990-11-09
AU3539489A (en)	1989-10-16
IL89790A0 (en)	1989-09-28
ZA907693B (en)	1992-05-27
CN1053924C (zh)	2000-06-28
CN1053265A (zh)	1991-07-24
CN1092712C (zh)	2002-10-16
ZA892397B (en)	1989-11-29
DE68929466D1 (de)	2003-06-26
ES2014593A6 (es)	1990-07-16
EP0411031A1 (de)	1991-02-06
DK234890A (da)	1990-11-30
DE68929466T2 (de)	2004-04-01
FI20002515A (fi)	2000-11-16
EP0411031A4 (en)	1992-02-05
ATE240973T1 (de)	2003-06-15
CA1340866C (en)	1999-12-28
DK234890D0 (da)	1990-09-28
DK175699B1 (da)	2005-01-24
FI904842A0 (fi)	1990-10-01
AU647371B2 (en)	1994-03-24
FI115528B (fi)	2005-05-31
CA1341443C (en)	2003-10-07
JPH04501502A (ja)	1992-03-19
EP0411031B1 (de)	2003-05-21
FI106316B (fi)	2001-01-15

Legal Events

Date	Code	Title	Description
2009-05-11	MK1K	Patent expired

Publication	Publication Date	Title
NO315944B1 (no)	2003-11-17	CR1 protein for diagnostisk anvendelse in vitro, dets nukleinsyresekvens, rekombinant celle uttrykkende CR1 proteinet og en fremgangsmåte forå rense et CR1 protein
US6316604B1 (en)	2001-11-13	Human C3b/C4b receptor (CR1)
US5981481A (en)	1999-11-09	Human C3b/C4b receptor (CR1)
AU656312B2 (en)	1995-02-02	The human C3b/C4b receptor (CR1)
JP3860605B2 (ja)	2006-12-20	補体活性化をブロックするキメラタンパク質
JP3136551B2 (ja)	2001-02-19	インターロイキン１β前駆体変換酵素をコードするＤＮＡ
FI102293B (fi)	1998-11-13	Ihmisen interleukiini-3:n molekulaarinen kloonaus ja ilmentäminen
US5208144A (en)	1993-05-04	Method for detection of human dna containing the gene encoding low density lipoprotein receptor
KR0143570B1 (ko)	1998-07-01	사람 C3b/C4b 수용체(CR1)단백질, 이의 정제 방법 및 이의 용도
NO310078B1 (no)	2001-05-14	Nukleinsyresekvens kodende for CR1-protein, ekspresjonsvektor samt rekombinant celle omfattende nevnte sekvens og en fremgangsmåte for å fremstille nevnte protein
AU647371C (en)	1995-05-25	The human C3b/C4b receptor (CR1)
US5304637A (en)	1994-04-19	Expression and purification of human interleukin-3 and muteins thereof
EP0435877A1 (de)	1991-07-10	Polynukleotide, die für den peptidkern menschlicher proteoglykane von effektorzellen der immunantwort kodieren
EP0358977A1 (de)	1990-03-21	Kloniertes Nephritis-Antigen
US6165744A (en)	2000-12-26	Isolation and characterization of cDNAs coding for the α, β, and γ subunits of the high-affinity receptor for immunoglobulin E
US5317085A (en)	1994-05-31	Polynucleotides that encode the human proteoglycan peptide core of the effector cells of the immune response